CXCL12 and acute myeloid leukemia: The anti-CXCR4 antibody ulocuplumab has shown to inhibit CXCL12-mediated cell migration and promote apoptosis in in vivo murine AML models as well as promoting chemosensitivity via mobilizing AML cells to circulation in clinical studies (139–141).